Xinchaotuo (sacubatril/allisartan) / Shenzhen Salubris - LARVOL DELTA

Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patients. (PubMed, J Geriatr Cardiol) - "In elderly patients with hypertension, sacubitril/allisartan provided dose-dependent greater blood pressure reductions compared with olmesartan."

Clinical • Journal • Cardiovascular • Hypertension

Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Monotherapy • Cardiovascular • Hypertension

Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. (PubMed, Am J Cardiovasc Drugs) - "This study supports that ARBs with inverse agonism, especially AZL-M, have a better BP-lowering efficacy compared with ARBs without inverse agonism and ARNIs, while maintaining favorable safety profiles. Future research is encouraged to explore the effects on long-term outcomes, combination therapies, and safety in diverse populations."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension

A multicenter, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the efficacy and safety of S086 combined with amlodipine in patients with essential hypertension whose (ChiCTR) - P3 | N=338 | Completed | Sponsor: Peking University First Hospital; Peking University First Hospital

Monotherapy • New P3 trial • Cardiovascular • Hypertension

S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P3 | N=5 | Recruiting | Sponsor: Shenzhen People's Hospital

New P3 trial • Cardiovascular • Congestive Heart Failure • Heart Failure